Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813930 | 0.90 | ADORA2A (0.57) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL1611240 | 0.90 | ADORA2A (0.57) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL7151768 | 0.87 | ADORA2A (0.46) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL8930520 | 0.85 | ADORA2A (0.48) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL7159475 | 0.85 | ADORA2A (0.46) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL217116 | 0.80 | CYP2C19 (0.60) | ADORA2AADORA2BADORA3CYP2C19ADORA1 | |
| SCHEMBL1612645 | 0.79 | PNP (0.56) | — | |
| SCHEMBL23813628 | 0.78 | HPGD (0.59) | — | |
| SCHEMBL21350965 | 0.78 | HPGD (0.59) | — | |
| SCHEMBL9347680 | 0.77 | ADORA2A (0.56) | SLC29A1ADORA2AADORA2BADORA3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187240-A1 | 2' -modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030004325-A1 | Sugar modified oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6399754-B1 | CONTAINING SULFOPHOSPHATE GROUP | ISIS PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6307040-B1 | MIXED SEQUENCE OLIGONUCLEOTIDE HAVING AT LEAST ONE MODIFIED 2'-DEOXYFURANOSYL MOIETY MODIFIED BY SUBSTITUTION WITH HALO, AZIDO, AMINO, SUBSTITUTED AMINO, HALOMETHYL, CYANATO, HALOALKOXYL, ALKYL SULFIDE OR SULFONATE, NITRATE OR NITRITE | ISIS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0549615-A4 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0549615-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992003568-A1 | SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-03-05 | — | — | WO | disclosed |